Evidence map›Paper›PMID 30064728›Full record

ArticleSeminars in arthritis and rheumatism2019

Methodological considerations in comparing access to Pre-emptive renal transplantation between SLE and other ESRD causes in the USRDS.

Anna Broder, Wenzhu B Mowrey, Ladan Golestaneh, Chaim Putterman, Karen H Costenbader, Mimi Kim

Open access · greenAbstract read
In one paragraph

Article in Seminars in arthritis and rheumatism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anna BroderDivision of Rheumatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States. Electronic address: abroder@montefiore.org.
Wenzhu B MowreyDivision of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: wenzhu.mowrey@einstein.yu.edu.
Ladan GolestanehDivision of Nephrology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States. Electronic address: lgolesta@montefiore.org.
Chaim PuttermanDivision of Rheumatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: chaim.putterman@einstein.yu.edu.
Karen H CostenbaderDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: kcostenbader@partners.org.
Mimi KimDivision of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: mimi.kim@einstein.yu.edu.
Albert Einstein College of Medicine · USBrigham and Women's Hospital · US

Funding

CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial FactorsR01AR057327 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2009 to 2019
$6.2M
Cardiovascular Disease Epidemiology in Patients with LupusK24AR066109 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2014 to 2023
$1.7M
The impact of hydroxychloroquine use on thrombosis and mortality in lupus-related end stage renal diseaseK23AR068441 · NIAMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BRODER, ANNA · 2017 to 2021
$832k
NCATS NIH HHS UL1 TR002556NIAMS NIH HHS K23 AR068441NIAMS NIH HHS K24 AR066109NIAMS NIH HHS R01 AR057327
6 · The paper itself

Abstract

backgroundWe compared pre-emptive transplant rates between SLE and non-SLE end-stage renal disease (ESRD) from the U.S. Renal Data System (USRDS) and investigated the potential influence of frequency matching and primary ESRD causes in the non-SLE group.

methods4830 adult SLE patients with incident ESRD from USRDS 2005-2009 were frequency matched by age, sex and race to 4830 patients with incident non-SLE ESRD. Multivariable logistic regression models were used to estimate the odds of pre-emptive transplantation in SLE and non-SLE, and with the non-SLE subgroups by primary ESRD cause.

resultsThe odds ratios (OR) of receiving a pre-emptive transplant were similar among non-SLE and SLE (referent group): OR = 1.18 (95% CI: 0.92, 1.50; p = 0.20). However, the ORs for receiving a pre-emptive transplant were 0.19 (95% CI: 0.08, 0.42) in type 2 diabetes ESRD, 0.42 (95% CI: 0.23, 0.75) for hypertension-associated ESRD, 1.67 (95% CI: 1.10, 2.54) in type 1 diabetes ESRD, and 2.06 (95% CI: 1.55, 2.73) for "other" ESRD. In contrast to non-SLE, younger SLE patients were less likely to receive a pre-emptive transplant than older SLE patients.

conclusionThe results of this study provide compelling evidence that major improvements need to be made in optimizing access to pre-emptive transplantation in SLE by addressing sociodemographic disparities and the unique challenges faced by SLE patients. Applying careful matching and selecting appropriate comparison groups in future studies may facilitate the development of effective strategies to address these barriers and to increase the number of pre-emptive renal transplants among SLE patients.

Indexed as

Kidney TransplantationAdultDatabases, FactualFemaleHealth Services AccessibilityHumansKidney Failure, ChronicLupus Erythematosus, SystemicMaleMiddle AgedRisk FactorsTime FactorsYoung AdultDiabetes mallitusEnd-stage renal diseaseLupus nephritisRenal transplantationSystemic lupus erythematosus

Identifiers

PMID30064728
PMCPMC6291358
OpenAlexW2808641624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.